Michael Grey has served on the board of directors since September 2011 and as lead independent director of the company since August 2012. Grey has served as chairman of the board of directors of Mirum Pharmaceuticals Inc., a public biotechnology company, since January 2020, and as executive chairman from March 2019 to December 2019. Before that he served as chief executive officer of Mirum from the company’s inception in March 2018. He has served as executive chairman of Spruce Biosciences Inc., a public biotechnology company, since April 2017; Amplyx Pharmaceuticals Inc., a private pharmaceutical company, since January 2017; Reneo Pharmaceuticals Inc., a private pharmaceutical company, since December 2017; and as chairman of Plexium Inc., a private biotechnology company, since August 2020. He has also served as a venture partner at Pappas Ventures since January 2010. Grey served from October 2015 to January 2017 as the president and chief executive officer of Amplyx, from September 2014 to December 2017 as chairman and chief executive officer of Reneo and from May 2019 until April 2020 as executive chairman of Curzion Pharmaceuticals Inc., a private pharmaceutical company. From February 2011 to June 2014, Grey served as president and chief executive officer of Lumena Pharmaceuticals Inc., a biotechnology company, which was acquired by Shire plc in June 2014. He has 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including president and chief executive officer of SGX Pharmaceuticals Inc. (sold to Eli Lilly and Company in 2008), president and chief executive officer of Trega Biosciences Inc. (sold to LION Bioscience Inc. in 2001) and president of BioChem Therapeutic Inc. Before these, Grey served in various roles with Glaxo Inc. and Glaxo Holdings plc, culminating in his position as vice president, corporate development and director of international licensing. Grey also serves on the boards of directors of BioMarin Pharmaceutical Inc. and Mirati Therapeutics Inc., both public biotechnology companies.
Grey received a Bachelor of Science in chemistry from the University of Nottingham in the United Kingdom.
What is Michael G. Grey's net worth?
The estimated net worth of Michael G. Grey is at least $1.74 million as of April 12th, 2021. Mr. Grey owns 15,000 shares of Horizon Therapeutics Public stock worth more than $1,744,500 as of December 18th. This net worth approximation does not reflect any other assets that Mr. Grey may own. Learn More about Michael G. Grey's net worth.
How do I contact Michael G. Grey?
Has Michael G. Grey been buying or selling shares of Horizon Therapeutics Public?
Michael G. Grey has not been actively trading shares of Horizon Therapeutics Public over the course of the past ninety days. Most recently, Michael G. Grey sold 5,000 shares of the business's stock in a transaction on Thursday, July 22nd. The shares were sold at an average price of $100.04, for a transaction totalling $500,200.00. Learn More on Michael G. Grey's trading history.
Who are Horizon Therapeutics Public's active insiders?
Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.
